TRP2 mRNA-electroporated autologous langerhans-type dendritic cell vaccine

{
  "id": "MLC-T-ONC-017352",
  "term": "TRP2 mRNA-electroporated autologous langerhans-type dendritic cell vaccine",
  "field": "Oncology and biomedicine",
  "definition": "A cancer cell vaccine composed of autologous human Langerhans-type dendritic cells (also known as Langerhans cells or LCs) that are electroporated with mRNA encoding full-length murine tyrosinase-related peptide 2 (TRP2), with potential antineoplastic and immunomodulating activities. Upon vaccination, the TRP2 mRNA-electroporated autologous Langerhans-type dendritic cell vaccine may stimulate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against TRP2-expressing tumor cells. TRP2, a tautomerase involved in the synthesis of melanin, is only expressed in melanomas, melanocytes, and the retina. The LCs are differentiated from CD34 positive hematopoietic progenitor cells.",
  "synonyms": [
    "autologous Langerhans-type mRNA-electroporated dendritic cell vaccine"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/trp2-mrna-electroporated-autologous-langerhans-type-dendritic-cell-vaccine/"
}